Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00905424 · ClinicalTrials.gov registry record · Phase 2
Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant
A Phase 2 study, sponsored by Shire.
- Completed
- Registry status
- Phase 2
- Development phase
- 246
- Enrollment target
NCT00905424 is a Phase 2 study that has completed, run by Shire. The registered enrollment target is 246 participants.
The verdict
NCT00905424, a Phase 2 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 246 participants
- Enrollment target
Study Summary
To evaluate the efficacy of SPD489 when used as augmentation to an antidepressant in the treatment of major depressive disorder (MDD) as measured by mean change in total Montgomery-Ǻsberg Depression Rating Scale (MADRS) scores.
Interventions
- DRUG Antidepressant + placebo
- DRUG Antidepressant + SPD489 (lisdexamfetamine dimesylate)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2009-07-30 |
| Est. Completion | 2010-08-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00905424
The ClinicalTrials.gov registry entry for NCT00905424 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 246 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Antidepressant + placebo is the first listed.
NCT00905424 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00905424 about?
NCT00905424 is a clinical study titled "Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant". To evaluate the efficacy of SPD489 when used as augmentation to an antidepressant in the treatment of major depressive disorder (MDD) as measured by mean change in total Montgomery-Ǻsberg Depression Rating Scale (MADRS) scores.
What is the current status of trial NCT00905424?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 246 participants. The study started on 2009-07-30. Estimated completion is 2010-08-04.
What interventions are being tested in trial NCT00905424?
The interventions under investigation include: Antidepressant + placebo (DRUG), Antidepressant + SPD489 (lisdexamfetamine dimesylate) (DRUG).
Who is sponsoring clinical trial NCT00905424?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.